Clinical Trial Update: Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 study evaluating the efficacy and safety of oral PF-06651600 and PF-06700841 in moderate-to-severe Crohn's disease, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• PF-06651600 (PF-06651600)
• PF-06700841

Snippet

Sponsor: Pfizer | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-10-30